Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus DETROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus DETROL.
CANTIL vs DETROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic